New obesity drug SYH2082 enters first human safety trial

NCT ID NCT07532655

Not yet recruiting Disease control Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study tests a single dose of SYH2082 injection in 44 healthy adults who are overweight or have obesity. The main goal is to check safety and side effects, not weight loss. Participants will receive either the drug or a placebo, and researchers will monitor how the drug moves through the body. This is an early step to see if the drug is safe enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYH2082 injection
What this could lead to: If this early study shows the drug is safe, it could lead to a new treatment option for managing obesity.
What could go wrong: This is a very early Phase 1 trial with only 44 healthy people, so it is not designed to prove the drug works for weight loss. The drug may cause side effects or fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

More trials for these conditions

Other studies related to the condition(s) this trial covers.